Xlife Sciences AG Statistics

Total Valuation

Xlife Sciences AG has a market cap or net worth of CHF 143.54 million. The enterprise value is 293.05 million.

Market Cap	143.54M
Enterprise Value	293.05M

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Xlife Sciences AG has 5.74 million shares outstanding. The number of shares has increased by 12.33% in one year.

Current Share Class	n/a
Shares Outstanding	5.74M
Shares Change (YoY)	+12.33%
Shares Change (QoQ)	-19.60%
Owned by Insiders (%)	49.73%
Owned by Institutions (%)	2.16%
Float	2.89M

Valuation Ratios

The trailing PE ratio is 9.58.

PE Ratio	9.58
Forward PE	n/a
PS Ratio	142.51
PB Ratio	0.52
P/TBV Ratio	n/a
P/FCF Ratio	75.57
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	13.80
EV / Sales	295.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	154.28

Financial Position

The company has a current ratio of 2.70, with a Debt / Equity ratio of 0.15.

Current Ratio	2.70
Quick Ratio	2.69
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	29.19
Interest Coverage	-61.15

Financial Efficiency

Return on equity (ROE) is 4.47% and return on invested capital (ROIC) is -2.88%.

Return on Equity (ROE)	4.47%
Return on Assets (ROA)	-2.36%
Return on Capital (ROIC)	-2.88%
Revenue Per Employee	58,251
Profits Per Employee	1.25M
Employee Count	17
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.90% in the last 52 weeks. The beta is 0.54, so Xlife Sciences AG's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	-49.90%
50-Day Moving Average	26.23
200-Day Moving Average	31.30
Relative Strength Index (RSI)	45.53
Average Volume (20 Days)	5,438

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Xlife Sciences AG had revenue of CHF 990,274 and earned 21.24 million in profits. Earnings per share was 2.61.

Revenue	990,274
Gross Profit	539,341
Operating Income	-18.66M
Pretax Income	10.92M
Net Income	21.24M
EBITDA	-2.74M
EBIT	-18.66M
Earnings Per Share (EPS)	2.61

Full Income Statement

Balance Sheet

The company has 99,776 in cash and 55.45 million in debt, giving a net cash position of -55.35 million or -9.64 per share.

Cash & Cash Equivalents	99,776
Total Debt	55.45M
Net Cash	-55.35M
Net Cash Per Share	-9.64
Equity (Book Value)	366.98M
Book Value Per Share	47.84
Working Capital	11.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.91 million and capital expenditures -13,903, giving a free cash flow of 1.90 million.

Operating Cash Flow	1.91M
Capital Expenditures	-13,903
Free Cash Flow	1.90M
FCF Per Share	0.33

Full Cash Flow Statement

Margins

Gross margin is 54.46%, with operating and profit margins of -1,884.63% and 2,144.50%.

Gross Margin	54.46%
Operating Margin	-1,884.63%
Pretax Margin	1,103.19%
Profit Margin	2,144.50%
EBITDA Margin	-277.04%
EBIT Margin	n/a
FCF Margin	191.82%

Dividends & Yields

Xlife Sciences AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.33%
Shareholder Yield	-12.33%
Earnings Yield	10.44%
FCF Yield	1.32%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Xlife Sciences AG has an Altman Z-Score of 1.14. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.14
Piotroski F-Score	n/a